VahatiCor Achieves Success with A-FLUX Reducer System™ Trials
VahatiCor, a trailblazer in cardiovascular innovation, proudly announces significant results from its compassionate use study of the A-FLUX Reducer System™. This initiative was designed to aid patients suffering from obstructive coronary artery disease and symptomatic coronary microvascular dysfunction (CMD). The study, which involved ten patients with varying conditions, marks a pivotal moment in validating both the safety and preliminary effectiveness of this novel therapeutic approach.
Significant Outcomes from the Compassionate Use Study
The results of the compassionate use study show that patients reported notable reductions in symptoms, returning to their daily routines with minimal recovery time. This emphasizes the potential of the A-FLUX Reducer System in managing CMD, which often afflicts patients with limited treatment options. The A-FLUX device demonstrated an average implantation procedure time of just nine minutes, showcasing its efficiency and the advancements in minimally invasive procedures.
Next Steps: SERRA-I U.S. Early Feasibility Study
Encouraged by the promising outcomes, VahatiCor plans to initiate SERRA-I, a U.S.-based early feasibility study specifically targeting patients with CMD. The trial will be co-led by esteemed coronary physiology experts Samit Shah, MD, PhD, FACC, and Tim Van de Hoef, MD, PhD, FESC. Their involvement underscores the importance of this research and the commitment to advancing treatment for CMD patients.
Innovative Features of the A-FLUX Reducer System
The A-FLUX Reducer System is equipped with advanced SwiftCell Technology™, which strategically redistributes oxygen to the heart's sub-endocardial layer. This design is particularly beneficial for patients who, despite undergoing invasive angiography, are found to have CMD rather than obstructive coronary artery disease. With CMD impacting a significant portion of the population, particularly women, the A-FLUX System provides a unique solution that may transform patient care.
Unmet Clinical Needs in CMD Treatment
CMD often remains underdiagnosed, leading to persistent symptoms that significantly affect patients' quality of life. Millions globally experience the debilitating effects of chest pressure and discomfort without effective treatment options. Untreated CMD can lead to severe complications, including an increased risk of mortality. As Dr. Shah noted, there is a pressing demand for effective interventions to improve patient outcomes, making the A-FLUX Reducer System a vital step forward.
About VahatiCor and Its Vision
VahatiCor, Inc. is dedicated to transforming the landscape of coronary microvascular dysfunction through cutting-edge technologies and innovative therapies. By focusing on minimizing patient recovery times and enhancing overall well-being, VahatiCor aims to empower individuals affected by these challenging conditions.
The A-FLUX Reducer System signifies not only a technological advancement but also hope for many patients seeking relief from CMD. As research progresses, the potential for wider application and acceptance of this device becomes increasingly viable.
Frequently Asked Questions
What is the A-FLUX Reducer System?
The A-FLUX Reducer System is a minimally invasive device designed to improve blood flow in patients with coronary microvascular dysfunction (CMD).
What were the results of the compassionate use study?
The study demonstrated a significant reduction in symptoms for patients with obstructive coronary artery disease and CMD, with fast recovery times.
Who are the co-principal investigators for the upcoming study?
The upcoming study will be co-led by Dr. Samit Shah and Dr. Tim Van de Hoef, who are both prominent cardiologists in this field.
What is CMD and why is it important to treat?
Coronary microvascular dysfunction (CMD) is a condition where small coronary arteries fail to dilate properly, leading to significant chest pain and other symptoms, needing effective treatment options.
How does the A-FLUX Reducer System work?
The system utilizes SwiftCell Technology™ to enhance oxygen delivery to the heart muscle, thereby alleviating symptoms associated with CMD.
